Drug intelligence / Profile preview

chidamide + rituximab + methotrexate

Development stage: Unknown
Lead developer: Akeso
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of chidamide (a histone deacetylase inhibitor), rituximab (an anti-CD20 monoclonal antibody), and methotrexate (an immunosuppressant). This regimen is being investigated primarily for the treatment of B-cell lymphomas, particularly diffuse large B-cell lymphoma (DLBCL). Chidamide enhances rituximab's effectiveness by counteracting CD20 downregulation and synergizing with rituximab-mediated cytotoxicity, while methotrexate provides additional immunosuppressive effects.

Targets

CD20 (B-lymphocyte antigen CD20)HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on chidamide + rituximab + methotrexate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on chidamide + rituximab + methotrexate.